References
- Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344:783–792.
- Romond EH, et al. Trastuzumab plus adjuvant chemother-apy for operable HER2-positive breast cancer. N Engl J Med 2005353:1673-1684.
- Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353: 1659–1672.
- Slamon D, Eierman W, Pienkowski T, Martin M, Pawlick M, et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC- >T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC- >TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG O06 study. Breast Cancer Res Treat 2005;94\(Suppl 1) (abstract 1).
- Perez EA, Suman VJ, Davidson N, Martino S, Kaufman P. NCCTG N9831 Update. Presented at the 41st Annual Meeting of the American Society of Clinical Oncology; 2005.
- Pegram M, Hsu S, Lewis G, Pietras R, Beryt M, Sliwkowski M, Coombs D, Baly D, Kabbinavar F, Slamon D. Inhibitory effects of combinations of HER-2/ neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 1999 Apr 1;18(13):2241–2251.